Making the Case for Molecular Staging of Malignant Pleural Mesothelioma

Seminars in Thoracic and Cardiovascular Surgery

Volumn 21, Issue 2, 2009, Pages 188-193

  Bueno, Raphael ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

gene ratio test; mesothelioma; outcome in mesothelioma; predictive test; RNA expression; staging of mesothelioma; surgery in mesothelioma

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PREDICTION; PROGNOSIS;

BIOPSY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESOTHELIOMA; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; PATIENT SELECTION; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; THORACIC SURGICAL PROCEDURES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 70349729974     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2009.07.003     Document Type: Article

References (55)

1. Pass H.I. Malignant pleural mesothelioma: Surgical roles and novel therapies. Clin Lung Cancer 3 (2001) 102-117
2. Sugarbaker D.J., Norberto J.J., and Bueno R. Current therapy for mesothelioma. Cancer Control 4 (1997) 326-334
3. Flores R.M., Pass H.I., Seshan V.E., et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients. 626, e1-e3. J Thorac Cardiovasc Surg 135 (2008) 620-626
4. Pass H.I., Robinson B.W., Testa J.R., et al. Emerging translational therapies for mesothelioma. Chest 116 (1999) 455S-460S
5. Sugarbaker D.J., Strauss G.M., Lynch T.J., et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 11 (1993) 1172-1178
6. Sugarbaker D.J., Garcia J.P., Richards W.G., et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 224 (1996) 288-294, discussion, 294-296
7. Sugarbaker D.J., and Liptay M.J. Therapeutic approaches in malignant mesothelioma. In: Aisner J., Arriagada R., Green M.R., et al. (Eds). Comprehensive Textbook of Thoracic Oncology (1996), Williams and Wilkins, Baltimore, MD 786-798
8. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 117 (1999) 54-63, discussion, 63-65
9. Sugarbaker D.J. Macroscopic complete resection: The goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol 1 (2006) 175-176
10. Zellos L., and Sugarbaker D.J. Current surgical management of malignant pleural mesothelioma. Curr Oncol Rep 4 (2002) 354-360
11. Zellos L., Richards W.G., Capalbo L., et al. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 137 (2009) 453-458
12. Sugarbaker D.J., Jaklitsch M.T., Bueno R., et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 128 (2004) 138-146
13. Richards W.G., Zellos L., Bueno R., et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 24 (2006) 1561-1567
14. Gordon G.J., Jensen R.V., Hsiao L.L., et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62 (2002) 4963-4967
15. Gordon G.J., Jensen R.V., Hsiao L.L., et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 95 (2003) 598-605
16. Gordon G.J., Rockwell G.N., Godfrey P.A., et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 11 (2005) 4406-4414
17. Gordon G.J., Dong L., Yeap B.Y., et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst 101 (2009) 678-686
18. Toyooka S., Kishimoto T., and Date H. Advances in the molecular biology of malignant mesothelioma. Acta Med Okayama 62 (2008) 1-7
19. Edwards J.G., Abrams K.R., Leverment J.N., et al. Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems. Thorax 55 (2000) 731-735
20. Flores R.M., Zakowski M., Venkatraman E., et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2 (2007) 957-965
21. Bueno R., Reblando J., Glickman J., et al. Pleural biopsy: A reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg 78 (2004) 1774-1776
22. Tournoy K.G., Burgers S.A., Annema J.T., et al. Transesophageal endoscopic ultrasound with fine needle aspiration in the preoperative staging of malignant pleural mesothelioma. Clin Cancer Res 14 (2008) 6259-6263
23. Rice D.C., Erasmus J.J., Stevens C.W., et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg 80 (2005) 1988-1992, discussion, 1992-1993
24. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma. From The International Mesothelioma Interest Group. Chest 108 (1995) 1122-1128
25. Alvarez J.M., Ha T., Musk W., et al. Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy. J Thorac Cardiovasc Surg 130 (2005) 905-906
26. Van Schil P. Malignant pleural mesothelioma: Staging systems. Lung Cancer 49 suppl 1 (2005) S45-S48
27. van Meerbeeck J.P., and Boyer M. Consensus report: Pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. Lung Cancer 49 suppl 1 (2005) S123-S127
28. Heelan R. Staging and response to therapy of malignant pleural mesothelioma. Lung Cancer 45 suppl 1 (2004) S59-S61
29. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 14 (1996) 1-12
30. Jett J.R. Malignant pleural mesothelioma. A proposed new staging system. Chest 108 (1995) 895-897
31. Boutin C., Rey F., Gouvernet J., et al. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 72 (1993) 394-404
32. Pass H.I., Liu Z., Wali A., et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 10 (2004) 849-859
33. Kettunen E., Nissen A.M., Ollikainen T., et al. Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int J Cancer 91 (2001) 492-496
34. Borczuk A.C., Cappellini G.C., Kim H.K., et al. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 26 (2007) 610-617
35. Lopez-Rios F., Chuai S., Flores R., et al. Global gene expression profiling of pleural mesotheliomas: Overexpression of Aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66 (2006) 2970-2979
36. Musti M., Kettunen E., Dragonieri S., et al. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet 170 (2006) 9-15
37. Christensen B.C., Godleski J.J., Marsit C.J., et al. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis 29 (2008) 1555-1559
38. Gordon G.J. Transcriptional profiling of mesothelioma using microarrays. Lung Cancer 49 suppl 1 (2005) S99-S103
39. Gordon G.J., Deters L.A., Nitz M.D., et al. Differential diagnosis of solitary lung nodules with gene expression ratios. J Thorac Cardiovasc Surg 132 (2006) 621-627
40. Gordon G.J., Richards W.G., Sugarbaker D.J., et al. A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer Epidemiol Biomarkers Prev 12 (2003) 905-910
41. Ma X.J., Wang Z., Ryan P.D., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cells 5 (2004) 607-616
42. Ankerst D.P., Groskopf J., Day J.R., et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol 180 (2008) 1303-1308, discussion, 1308
43. Deras I.L., Aubin S.M., Blase A., et al. 3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 179 (2008) 1587-1592
44. Hofmann H.S., Hansen G., Burdach S., et al. Discrimination of human lung neoplasm from normal lung by two target genes. Am J Respir Crit Care Med 170 (2004) 516-519
45. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
46. van 't Veer L.J., Dai H., Van De Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
47. Reid J.F., Lusa L., De Cecco L., et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 97 (2005) 927-930
48. Muggerud A.A., Johnsen H., Barnes D.A., et al. Evaluation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes. BMC Cancer 6 (2006) 59
49. Finak G., Sadekova S., Pepin F., et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res 8 (2006) R58
50. Hu M., and Polyak K. Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer 44 (2008) 2760-2765
51. Ma X.J., Dahiya S., Richardson E., et al. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 11 (2009) R7
52. Quackenbush J. Computational analysis of microarray data. Nat Rev Genet 2 (2001) 418-427
53. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 354 (2006) 2463-2472
54. Van De Vijver M.J., He Y.D., Van'T Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
55. Richards W., Van Oss S., Glickman J., et al. A microaliquoting technique for precise histological annotation and optimization of cell content in frozen tissue specimens. Biotech Histochem 3 (2007) 1-9